{"id":"e3b2b1ac124c","type":"article","url":"https://hartvaat.nl/2026/01/22/finerenon-verbetert-albuminurie-via-mr-trpc-signalering-bij-diabetische-nierziek/","title":"Finerenon verbetert albuminurie via MR-TRPC-signalering bij diabetische nierziekte","title_en":"Finerenone Improves Albuminuria via MR-TRPC Signaling in Diabetic Kidney Disease","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","internist"],"tags":["anemie-ckd","cardiorenal-behandelstrategie","chronische-nierziekte","diabetes-en-hart","dyslipidemie","fidelio-dkd","fidelity","figaro-dkd","finerenon","finerenon-hartfalen-nierziekte","mra-aldosteronantagonisten","tirzepatide"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25739","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25739","authors":["Tsukasa Iwakura"],"significance":5,"published":"2026-01-22","source_date":"2026-01-22","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/","https://hartvaat.nl/kennis/nierziekte/diabetische-nefropathie/"],"congress":"","summary_en":"This study reveals that finerenone improves albuminuria in diabetic kidney disease through the mineralocorticoid receptor-TRPC signalling pathway, protecting podocytes by limiting excessive calcium influx via TRPC5 channels.","created":"2026-07-03T10:25:31Z","updated":"2026-07-03T13:24:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Recente studies bevestigen de beschermende effecten van niet-steroïdale MR-antagonisten bij diabetische nierziekte. Dit onderzoek onthult dat finerenon de albuminurie verbetert via MR-TRPC-signalering, wat het fysiologische mechanisme verduidelijkt.","abstract_original":"Hypertension, Volume 83, Issue 4, Page e25739, April 1, 2026. BACKGROUND:Recent studies have confirmed the protective effects of nonsteroidal MR (mineralocorticoid receptor) antagonists in diabetic kidney disease. However, the physiological mechanisms underlying their albuminuria-reducing effects remain incompletely defined. We hypothesized that inhibition of the MR could protect podocytes by limiting excessive calcium influx via TRPC (transient receptor potential canonical) 5, thereby reducing albuminuria.METHODS:We evaluated the effects of the nonsteroidal MR antagonist finerenone on albuminuria, podocyte morphology, and glomerular function in diabetic mice. Reactive oxygen species generation and single-nephron glomerular filtration rate were analyzed using in vivo imaging. Cultured podocytes were used to assess MR-TRPC5 signaling through measurements of Sgk1 (serum- and glucocorticoid-regulated kinase 1) and TRPC5 expression, intracellular calcium, and actin cytoskeletal organizatio"}